The DOI matches its Crossref record; 98 of the 98 references it cites were found in a registry or an index.
Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections
Open accessAbstract
BACKGROUND: Acute respiratory infections (ARIs) comprise of a large and heterogeneous group of infections including bacterial, viral, and other aetiologies. In recent years, procalcitonin (PCT), a blood marker for bacterial infections, has emerged as a promising tool to improve decisions about antibiotic therapy (PCT-guided antibiotic therapy). Several randomised controlled trials (RCTs) have demonstrated the feasibility of using procalcitonin for starting and stopping antibiotics in different patient populations with ARIs and different settings ranging from primary care settings to emergency departments, hospital wards, and intensive care units. However, the effect of using procalcitonin on clinical outcomes is unclear. This is an update of a Cochrane review and individual participant data meta-analysis first published in 2012 designed to look at the safety of PCT-guided antibiotic stewardship. OBJECTIVES: The aim of this systematic review based on individual participant data was to assess the safety and efficacy of using procalcitonin for starting or stopping antibiotics over a large range of patients with varying severity of ARIs and from different clinical settings. SEARCH METHODS: We searched the Cochrane Central Register of Controlled Trials (CENTRAL), which contains the Cochrane Acute Respiratory Infections Group's Specialised Register, MEDLINE, and Embase, in February 2017, to identify suitable trials. We also searched ClinicalTrials.gov to identify ongoing trials in April 2017. SELECTION CRITERIA: We included RCTs of adult participants with ARIs who received an antibiotic treatment either based on a procalcitonin algorithm (PCT-guided antibiotic stewardship algorithm) or usual care. We excluded trials if they focused exclusively on children or used procalcitonin for a purpose other than to guide initiation and duration of antibiotic treatment. DATA COLLECTION AND ANALYSIS: Two teams of review authors independently evaluated the methodology and extracted data from primary studies. The primary endpoints were all-cause mortality and treatment failure at 30 days, for which definitions were harmonised among trials. Secondary endpoints were antibiotic use, antibiotic-related side effects, and length of hospital stay. We calculated odds ratios (ORs) and 95% confidence intervals (CIs) using multivariable hierarchical logistic regression adjusted for age, gender, and clinical diagnosis using a fixed-effect model. The different trials were added as random-effects into the model. We conducted sensitivity analyses stratified by clinical setting and type of ARI. We also performed an aggregate data meta-analysis. MAIN RESULTS: From 32 eligible RCTs including 18 new trials for this 2017 update, we obtained individual participant data from 26 trials including 6708 participants, which we included in the main individual participant data meta-analysis. We did not obtain individual participant data for four trials, and two trials did not include people with confirmed ARIs. According to GRADE, the quality of the evidence was high for the outcomes mortality and antibiotic exposure, and quality was moderate for the outcomes treatment failure and antibiotic-related side effects.Primary endpoints: there were 286 deaths in 3336 procalcitonin-guided participants (8.6%) compared to 336 in 3372 controls (10.0%), resulting in a significantly lower mortality associated with procalcitonin-guided therapy (adjusted OR 0.83, 95% CI 0.70 to 0.99, P = 0.037). We could not estimate mortality in primary care trials because only one death was reported in a control group participant. Treatment failure was not significantly lower in procalcitonin-guided participants (23.0% versus 24.9% in the control group, adjusted OR 0.90, 95% CI 0.80 to 1.01, P = 0.068). Results were similar among subgroups by clinical setting and type of respiratory infection, with no evidence for effect modification (P for interaction > 0.05). Secondary endpoints: procalcitonin guidance was associated with a 2.4-day reduction in antibiotic exposure (5.7 versus 8.1 days, 95% CI -2.71 to -2.15, P < 0.001) and lower risk of antibiotic-related side effects (16.3% versus 22.1%, adjusted OR 0.68, 95% CI 0.57 to 0.82, P < 0.001). Length of hospital stay and intensive care unit stay were similar in both groups. A sensitivity aggregate-data analysis based on all 32 eligible trials showed similar results. AUTHORS' CONCLUSIONS: This updated meta-analysis of individual participant data from 12 countries shows that the use of procalcitonin to guide initiation and duration of antibiotic treatment results in lower risks of mortality, lower antibiotic consumption, and lower risk for antibiotic-related side effects. Results were similar for different clinical settings and types of ARIs, thus supporting the use of procalcitonin in the context of antibiotic stewardship in people with ARIs. Future high-quality research is needed to confirm the results in immunosuppressed patients and pat
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139
Liberati, A., Altman, D. G., Tetzlaff, J., Mulrow, C., Gøtzsche, P. C., Ioannidis, J. P. A., Clarke, M., Devereaux, P. J., Kleijnen, J., & Moher, D. (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000100 · Cited by 28,164
Dermyshi, E., Wang, Y., Yan, C., Hong, W., Qiu, G., Gong, X., & Zhang, T. (2017) · Neonatology · doi:10.1159/000454668 · Cited by 24,451
Liberati, A., Altman, D. G., Tetzlaff, J., Mulrow, C., Gøtzsche, P. C., Ioannidis, J. P. A., Clarke, M., Devereaux, P. J., Kleijnen, J., & Moher, D. (2009) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2009.06.006 · Cited by 10,578
Grading quality of evidence and strength of recommendations
(2004) · BMJ · doi:10.1136/bmj.328.7454.1490 · Cited by 8,477
Kumar, A., Roberts, D., Wood, K. E., Light, B., Parrillo, J. E., Sharma, S., Suppes, R., Feinstein, D., Zanotti, S., Taiberg, L., et al. (2006) · Critical Care Medicine · doi:10.1097/01.ccm.0000217961.75225.e9 · Cited by 6,109
Outpatient antibiotic use in Europe and association with resistance: a cross-national database study
Goossens, H., Ferech, M., Vander Stichele, R., & Elseviers, M. (2005) · The Lancet · doi:10.1016/s0140-6736(05)17907-0 · Cited by 3,359
Stewart, L. A., Clarke, M., Rovers, M., Riley, R. D., Simmonds, M., Stewart, G., & Tierney, J. F. (2015) · JAMA · doi:10.1001/jama.2015.3656 · Cited by 2,134
Simon, L., Gauvin, F., Amre, D. K., Saint-Louis, P., & Lacroix, J. (2004) · Clinical Infectious Diseases · doi:10.1086/421997 · Cited by 1,787
Procalcitonin as a diagnostic marker for sepsis: A systematic review and meta-analysis.
Wacker, C., Prkno, A., Brunkhorst, F. M., & Schlattmann, P. (2013) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(12)70323-7 · Cited by 1,198
Cited by
Kalil, A. C., Metersky, M. L., Klompas, M., Muscedere, J., Sweeney, D. A., Palmer, L. B., Napolitano, L. M., O'Grady, N. P., Bartlett, J. G., Carratalà, J., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/ciw353 · Cited by 3,892
Metlay, J. P., Waterer, G. W., Long, A. C., Anzueto, A., Brozek, J., Crothers, K., Cooley, L. A., Dean, N. C., Fine, M. J., Flanders, S. A., et al. (2019) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201908-1581st · Cited by 3,657
Understanding the mechanisms and drivers of antimicrobial resistance
Holmes, A. H., Moore, L. S. P., Sundsfjord, A., Steinbakk, M., Regmi, S., Karkey, A., Guerin, P. J., & Piddock, L. J. V. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00473-0 · Cited by 2,611
Hotchkiss, R. S., Moldawer, L. L., Opal, S. M., Reinhart, K., Turnbull, I. R., & Vincent, J.-L. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.45 · Cited by 1,620
Self-citationVogelmeier, C. F., Criner, G. J., Martinez, F. J., Anzueto, A., Barnes, P. J., Bourbeau, J., Celli, B. R., Chen, R., Decramer, M., Fabbri, L. M., et al. (2017) · Respirology · doi:10.1111/resp.13012 · Cited by 681
Better Tests, Better Care: Improved Diagnostics for Infectious Diseases
Caliendo, A. M., Gilbert, D. N., Ginocchio, C. C., Hanson, K. E., May, L., Quinn, T. C., Tenover, F. C., Alland, D., Blaschke, A. J., Bonomo, R. A., et al. (2013) · Clinical Infectious Diseases · doi:10.1093/cid/cit578 · Cited by 628
Musher, D. M., & Thorner, A. R. (2014) · New England Journal of Medicine · doi:10.1056/nejmra1312885 · Cited by 626
Prina, E., Ranzani, O. T., & Torres, A. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60733-4 · Cited by 516
Procalcitonin-Guided Use of Antibiotics for Lower Respiratory Tract Infection
Huang, D. T., Yealy, D. M., Filbin, M. R., Brown, A. M., Chang, C.-C. H., Doi, Y., Donnino, M. W., Fine, J., Fine, M. J., Fischer, M. A., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1802670 · Cited by 434
Increased antimicrobial resistance during the COVID-19 pandemic
Lai, C.-C., Chen, S.-Y., Ko, W.-C., & Hsueh, P.-R. (2021) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2021.106324 · Cited by 436
Antibiotics for exacerbations of chronic obstructive pulmonary disease
Vollenweider, D. J., Jarrett, H., Steurer-Stey, C. A., Garcia-Aymerich, J., & Puhan, M. A. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010257 · Cited by 425
Li, X., Wang, L., Yan, S., Yang, F., Xiang, L., Zhu, J., Shen, B., & Gong, Z. (2020) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2020.03.053 · Cited by 402
Update on Procalcitonin Measurements
Meisner, M. (2014) · Annals of Laboratory Medicine · doi:10.3343/alm.2014.34.4.263 · Cited by 395
Antibiotic stewardship in the intensive care unit
Luyt, C.-E., Bréchot, N., Trouillet, J.-L., & Chastre, J. (2014) · Critical Care · doi:10.1186/s13054-014-0480-6 · Cited by 388
Self-citationPharmacokinetic-Pharmacodynamic Modeling of Antibacterial Drugs
Nielsen, E. I., & Friberg, L. E. (2013) · Pharmacological Reviews · doi:10.1124/pr.111.005769 · Cited by 332
ERS/ESICM/ESCMID/ALAT guidelines for the management of severe community-acquired pneumonia
Martin-Loeches, I., Torres, A., Nagavci, B., Aliberti, S., Antonelli, M., Bassetti, M., Bos, L. D., Chalmers, J. D., Derde, L., de Waele, J., et al. (2023) · Intensive Care Medicine · doi:10.1007/s00134-023-07033-8 · Cited by 316
Self-citationVogelmeier, C. F., Criner, G. J., Martínez, F. J., Anzueto, A., Barnes, P. J., Bourbeau, J., Celli, B. R., Chen, R., Decramer, M., Fabbri, L. M., et al. (2017) · Archivos de Bronconeumología · doi:10.1016/j.arbres.2017.02.001 · Cited by 309
Woods, C. R., Bradley, J. S., Chatterjee, A., Copley, L. A., Robinson, J., Kronman, M. P., Arrieta, A., Fowler, S. L., Harrison, C., Carrillo-Marquez, M. A., et al. (2021) · Journal of the Pediatric Infectious Diseases Society · doi:10.1093/jpids/piab027 · Cited by 308
Pugh, R., Grant, C., Cooke, R. P., & Dempsey, G. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007577.pub3 · Cited by 289
Russell, C. D., Parajuli, A., Gale, H. J., Bulteel, N. S., Schuetz, P., de Jager, C. P. C., Loonen, A. J. M., Merekoulias, G. I., & Baillie, J. K. (2019) · Journal of Infection · doi:10.1016/j.jinf.2019.02.006 · Cited by 287
Self-citationAcute Phase Reactants in Infections: Evidence-Based Review and a Guide for Clinicians
Markanday, A. (2015) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofv098 · Cited by 281
Schuetz, P., Briel, M., Christ-Crain, M., Stolz, D., Bouadma, L., Wolff, M., Luyt, C.-E., Chastre, J., Tubach, F., Kristoffersen, K. B., et al. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cis464 · Cited by 280
Self-citationProcalcitonin-guided diagnosis and antibiotic stewardship revisited
Sager, R., Kutz, A., Mueller, B., & Schuetz, P. (2017) · BMC Medicine · doi:10.1186/s12916-017-0795-7 · Cited by 280
Self-citationSchuetz, P., Beishuizen, A., Broyles, M., Ferrer, R., Gavazzi, G., Gluck, E. H., González del Castillo, J., Jensen, J.-U., Kanizsai, P. L., Kwa, A. L. H., et al. (2019) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2018-1181 · Cited by 279
Self-citationMurphy, C. N., Fowler, R., Balada-Llasat, J. M., Carroll, A., Stone, H., Akerele, O., Buchan, B., Windham, S., Hopp, A., Ronen, S., et al. (2020) · Journal of Clinical Microbiology · doi:10.1128/jcm.00128-20 · Cited by 269
Wirz, Y., Meier, M. A., Bouadma, L., Luyt, C. E., Wolff, M., Chastre, J., Tubach, F., Schroeder, S., Nobre, V., Annane, D., et al. (2018) · Critical Care · doi:10.1186/s13054-018-2125-7 · Cited by 265
Self-citationvan Engelen, T. S. R., Wiersinga, W. J., Scicluna, B. P., & van der Poll, T. (2018) · Critical Care Clinics · doi:10.1016/j.ccc.2017.08.010 · Cited by 178
Peng, F., Chang, W., Xie, J.-F., Sun, Q., Qiu, H.-B., & Yang, Y. (2019) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2019.05.034 · Cited by 49
Using Aggregate Patient Data at the Bedside via an On-Demand Consultation Service
Callahan, A., Gombar, S., Cahan, E. M., Jung, K., Steinberg, E., Polony, V., Morse, K., Tibshirani, R., Hastie, T., Harrington, R., et al. (2021) · NEJM Catalyst · doi:10.1056/cat.21.0224 · Cited by 24
Metadata
- Authors
- Schuetz, P., Wirz, Y., Sager, R., Christ-Crain, M., Stolz, D., Tamm, M., Bouadma, L., Luyt, C. E., Wolff, M., Chastre, J., Tubach, F., Kristoffersen, K. B., Burkhardt, O., Welte, T., Schroeder, S., Nobre, V., Wei, L., Bucher, H. C. C., Bhatnagar, N., Annane, D., Reinhart, K., Branche, A., Damas, P., Nijsten, M., de Lange, D. W., Deliberato, R. O., Lima, S. S., Maravić-Stojković, V., Verduri, A., Cao, B., Shehabi, Y., Beishuizen, A., Jensen, J.-U. S., Corti, C., Van Oers, J. A., Falsey, A. R., de Jong, E., Oliveira, C. F., Beghe, B., Briel, M., & Mueller, B.
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- Wiley
- Published
- 2017-10-12
- Volume
- 2019
- Issue
- 5
- Pages
- CD007498-CD007498
- ISSN
- 1361-6137 (ISSN-L)
- 1465-1858
- OpenAlex
- W2033541705
- Cited by
- 649
- References
- 98
- FWCI
- 43.35
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.